Document is current
Any future updates will be listed below
-
Authors
Paterson, Louise M. https://orcid.org/0000-0001-9137-4419
Cro, Suzie
Loebenberg, Gemma
Hazell, Lorna
Bagshaw, Amy
Smith, Claire
Lingford-Hughes, Anne R.
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/T025557/1)
- License Information
-
More Information
Article History
Received: 15 September 2025
Accepted: 21 July 2026
First Online: 11 September 2026
Ethics
Declarations: This study has been approved by the West of Scotland REC 1 committee (REC reference: 23/WS/0064), and has Clinical Trials Authorisation from the UK Competent Authority; MHRA/IRAS Reference: 1007293. Any important protocol modifications will be disseminated to the relevant parties by the research team and/or by regulatory bodies. Written, informed consent to participate will be obtained from all participants.All authors of the manuscript have read, contributed to, and agreed its content and consent to its publication.
Competing interests: ALH has funding from Indivior for a research study, is a member of Steering group for a trial led by Astra Zeneca, and advisor (unpaid) for Eli Lilly, Libero, Camurus, Opiant. She is Chair of Addiction Healthcare Goals, Office for Life Sciences, UK Government.LP has provided consultancy services to Indivior.All other authors declare that they have no competing interests.
